Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression

Amber L. Southwell, Stephen E P Smith, Tessa R. Davis, Nicholas S. Caron, Erika B. Villanueva, Yuanyun Xie, Jennifer A. Collins, Min Li Ye, Aaron Sturrock, Blair R. Leavitt, Adam G. Schrum, Michael R. Hayden

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Quantitation of huntingtin protein in the brain is needed, both as a marker of Huntington disease (HD) progression and for use in clinical gene silencing trials. Measurement of huntingtin in cerebrospinal fluid could be a biomarker of brain huntingtin, but traditional protein quantitation methods have failed to detect huntingtin in cerebrospinal fluid. Using micro-bead based immunoprecipitation and flow cytometry (IP-FCM), we have developed a highly sensitive mutant huntingtin detection assay. The sensitivity of huntingtin IP-FCM enables accurate detection of mutant huntingtin protein in the cerebrospinal fluid of HD patients and model mice, demonstrating that mutant huntingtin levels in cerebrospinal fluid reflect brain levels, increasing with disease stage and decreasing following brain huntingtin suppression. This technique has potential applications as a research tool and as a clinical biomarker.

Original languageEnglish (US)
Article number12166
JournalScientific Reports
Volume5
DOIs
StatePublished - Jul 15 2015

Fingerprint

Huntington Disease
Cerebrospinal Fluid
Brain
Immunoprecipitation
Flow Cytometry
Biomarkers
Gene Silencing
Mutant Proteins
Disease Progression
Huntingtin Protein
Research

ASJC Scopus subject areas

  • General

Cite this

Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. / Southwell, Amber L.; Smith, Stephen E P; Davis, Tessa R.; Caron, Nicholas S.; Villanueva, Erika B.; Xie, Yuanyun; Collins, Jennifer A.; Li Ye, Min; Sturrock, Aaron; Leavitt, Blair R.; Schrum, Adam G.; Hayden, Michael R.

In: Scientific Reports, Vol. 5, 12166, 15.07.2015.

Research output: Contribution to journalArticle

Southwell, AL, Smith, SEP, Davis, TR, Caron, NS, Villanueva, EB, Xie, Y, Collins, JA, Li Ye, M, Sturrock, A, Leavitt, BR, Schrum, AG & Hayden, MR 2015, 'Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression', Scientific Reports, vol. 5, 12166. https://doi.org/10.1038/srep12166
Southwell, Amber L. ; Smith, Stephen E P ; Davis, Tessa R. ; Caron, Nicholas S. ; Villanueva, Erika B. ; Xie, Yuanyun ; Collins, Jennifer A. ; Li Ye, Min ; Sturrock, Aaron ; Leavitt, Blair R. ; Schrum, Adam G. ; Hayden, Michael R. / Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. In: Scientific Reports. 2015 ; Vol. 5.
@article{1da5a6330a08482599db5db819f599ee,
title = "Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression",
abstract = "Quantitation of huntingtin protein in the brain is needed, both as a marker of Huntington disease (HD) progression and for use in clinical gene silencing trials. Measurement of huntingtin in cerebrospinal fluid could be a biomarker of brain huntingtin, but traditional protein quantitation methods have failed to detect huntingtin in cerebrospinal fluid. Using micro-bead based immunoprecipitation and flow cytometry (IP-FCM), we have developed a highly sensitive mutant huntingtin detection assay. The sensitivity of huntingtin IP-FCM enables accurate detection of mutant huntingtin protein in the cerebrospinal fluid of HD patients and model mice, demonstrating that mutant huntingtin levels in cerebrospinal fluid reflect brain levels, increasing with disease stage and decreasing following brain huntingtin suppression. This technique has potential applications as a research tool and as a clinical biomarker.",
author = "Southwell, {Amber L.} and Smith, {Stephen E P} and Davis, {Tessa R.} and Caron, {Nicholas S.} and Villanueva, {Erika B.} and Yuanyun Xie and Collins, {Jennifer A.} and {Li Ye}, Min and Aaron Sturrock and Leavitt, {Blair R.} and Schrum, {Adam G.} and Hayden, {Michael R.}",
year = "2015",
month = "7",
day = "15",
doi = "10.1038/srep12166",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression

AU - Southwell, Amber L.

AU - Smith, Stephen E P

AU - Davis, Tessa R.

AU - Caron, Nicholas S.

AU - Villanueva, Erika B.

AU - Xie, Yuanyun

AU - Collins, Jennifer A.

AU - Li Ye, Min

AU - Sturrock, Aaron

AU - Leavitt, Blair R.

AU - Schrum, Adam G.

AU - Hayden, Michael R.

PY - 2015/7/15

Y1 - 2015/7/15

N2 - Quantitation of huntingtin protein in the brain is needed, both as a marker of Huntington disease (HD) progression and for use in clinical gene silencing trials. Measurement of huntingtin in cerebrospinal fluid could be a biomarker of brain huntingtin, but traditional protein quantitation methods have failed to detect huntingtin in cerebrospinal fluid. Using micro-bead based immunoprecipitation and flow cytometry (IP-FCM), we have developed a highly sensitive mutant huntingtin detection assay. The sensitivity of huntingtin IP-FCM enables accurate detection of mutant huntingtin protein in the cerebrospinal fluid of HD patients and model mice, demonstrating that mutant huntingtin levels in cerebrospinal fluid reflect brain levels, increasing with disease stage and decreasing following brain huntingtin suppression. This technique has potential applications as a research tool and as a clinical biomarker.

AB - Quantitation of huntingtin protein in the brain is needed, both as a marker of Huntington disease (HD) progression and for use in clinical gene silencing trials. Measurement of huntingtin in cerebrospinal fluid could be a biomarker of brain huntingtin, but traditional protein quantitation methods have failed to detect huntingtin in cerebrospinal fluid. Using micro-bead based immunoprecipitation and flow cytometry (IP-FCM), we have developed a highly sensitive mutant huntingtin detection assay. The sensitivity of huntingtin IP-FCM enables accurate detection of mutant huntingtin protein in the cerebrospinal fluid of HD patients and model mice, demonstrating that mutant huntingtin levels in cerebrospinal fluid reflect brain levels, increasing with disease stage and decreasing following brain huntingtin suppression. This technique has potential applications as a research tool and as a clinical biomarker.

UR - http://www.scopus.com/inward/record.url?scp=84948830873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948830873&partnerID=8YFLogxK

U2 - 10.1038/srep12166

DO - 10.1038/srep12166

M3 - Article

C2 - 26174131

AN - SCOPUS:84948830873

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 12166

ER -